In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conceptus' Re-Birth: Surviving in Women's Health

Executive Summary

The early-to-mid 1990s marked the rise of a huge wave of interest in women's health among device start-ups and investors. Several women's health companies, including Conceptus, were among the ill-fated IPO Class of 1996 that largely failed to meet investor expectations. Most of these start-ups are no longer around, but Conceptus re-trenched and shifted its emphasis from fertility to a new approach to sterilization, which finally received FDA clearance late last year. The company has survived the pitfalls that derailed other women's health start-ups, most notably a customer group that is difficult to access and slow to adopt new technology, and a challenging reimbursement environment, but in doing so, may be the exception that proves the rule.

You may also be interested in...



Market & Industry Briefs

Brief summaries of recent medtech market and industry developments. This month we cover a new GAO report that ups the pressure on the medical imaging market; Cordis Corp.'s suspension of its PFO closure device program; Atritech's PMA for stroke prevention; Zimmer's acquisition of Abbott Spine; and the US market for contraception devices and procedures.

Novacept: A Patient Device Exit Strategy Succeeds

Using an aggressive clinical trials strategy to overcome early setbacks, Novacept is proof a small company can succeed in a big company market, and that a patient exit strategy can pay off for device companies--evidenced by Cytyc's $325 million cash acquisition of Novacept.

Novacept: A Patient Device Exit Strategy Succeeds

Using an aggressive clinical trials strategy to overcome early setbacks, Novacept is proof a small company can succeed in a big company market, and that a patient exit strategy can pay off for device companies--evidenced by Cytyc's $325 million cash acquisition of Novacept.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002176

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel